Nanotrap Lyme Antigen Test clinical study published
by Staff from Outbreak News Today on (#TABR)
Ceres Nanosciences, Inc. (Ceres) announced Tuesday the publication of a three year 300-person clinical study in the Journal of Translational Medicine. The study, titled: "Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl"terminus domain in early stage Lyme borreliosis" documents the development and data behind Ceres' groundbreaking test for Lyme ["]
